Informace o publikaci

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

Autoři

RÁČIL Zdeněk RÁZGA Filip DRÁPALOVÁ Jana BUREŠOVÁ Lucie ŽÁČKOVÁ Daniela PALACKOVÁ Martina SEMERÁD Lukáš MALÁSKOVÁ Ludmila HALUZÍK Martin MAYER Jiří

Druh Článek v odborném periodiku
Časopis / Zdroj Haematologica
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1
Doi http://dx.doi.org/10.3324/haematol.2013.086355
Obor Onkologie a hematologie
Klíčová slova Nilotinib; insulin resistance
Přiložené soubory
Popis For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.
Související projekty: